Moderna (MRNA) and CytomX (CTMX) Enter Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Moderna (MRNA) and CytomX (CTMX) Enter Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Moderna (MRNA) a catalyst driven idea at Morgan Stanley

January 6, 2023 12:17 PM EST

Morgan Stanley analyst Matthew Harrison labeled Moderna (NASDAQ: MRNA) a Catalyst Driven Idea in a note Friday, maintaining an Equal-Weight rating and $209 price target on the stock.

The analyst told investors the firm expects Moderna's first interim analysis from its Ph3 RSV vaccine study in the near term.

"We believe efficacy and... More

CytomX Therapeutics (CTMX) Climbs 50% Following Pact with Moderna on Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 5, 2023 4:37 PM EST

CytomX Therapeutics (NASDAQ: CTMX) Climbs 50% Following Pact with Moderna on Collaboration for mRNA-Based Conditionally Activated Therapeutics

... More

Morgan Stanley Calls Moderna (MRNA) a Catalyst Driven Idea

January 5, 2023 4:09 PM EST

Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $209.00 price target on Moderna (NASDAQ: MRNA).

The analyst comments "We expect the first interim analysis from Moderna's Ph3 RSV vaccine study in the near-term. We believe efficacy and safety in-between... More